Publications by authors named "Xinjian Cen"
Active learning, including student thinking and discussion in class, has been shown to increase student learning gains. However, it is less clear how instructor-level variation in the implementation and timing of active learning activities affects student gains. Our study aims to investigate the extent to which the time spent on individual episodes of active learning activities influences student performance.
View Article and Find Full Text PDFArticle Synopsis
- Cancer immunotherapy using autologous CAR T cells is complicated by manufacturing and patient selection issues, but 'off-the-shelf' options like allogeneic CAR-NKT cells could simplify the process.
- Researchers developed a new method to produce high-yield IL-15-enhanced CAR-NKT cells that target multiple cancers, showing effectiveness in battling multiple myeloma and removing immunosuppressive cells from tumors.
- The CAR-NKT cells demonstrated a stable hypoimmunogenic profile, meaning they are less likely to cause harmful immune reactions, making them promising candidates for clinical use without severe side effects like graft versus host disease.
The clinical potential of current FDA-approved chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy is encumbered by its autologous nature, which presents notable challenges related to manufacturing complexities, heightened costs, and limitations in patient selection. Therefore, there is a growing demand for off-the-shelf universal cell therapies. In this study, we have generated universal CAR-engineered NKT (CAR-NKT) cells by integrating iNKT TCR engineering and HLA gene editing on hematopoietic stem cells (HSCs), along with an ex vivo, feeder-free HSC differentiation culture.
View Article and Find Full Text PDFArticle Synopsis
- Allogeneic Vγ9Vδ2 T cells show promise for cancer therapy due to their safety and tumor-fighting abilities, but their clinical effectiveness has been limited by donor variability and other factors.
- Researchers are enhancing these T cells by selecting donors based on a biomarker (CD16), which improves their immune response and functionality, supported by RNA sequencing.
- Preclinical studies in ovarian cancer models confirm that these engineered CD16 Vδ2 T cells are effective, safe, and persist within the body, making them a potential new therapy for treating cancer.
Cell-based cancer immunotherapy, such as chimeric antigen receptor (CAR) engineered T and natural killer (NK) cell therapies, has become a revolutionary new pillar in cancer treatment. Interleukin 15 (IL-15), a potent immunostimulatory cytokine that potentiates T and NK cell immune responses, has demonstrated the reliability and potency to potentially improve the therapeutic efficacy of current cell therapy. Structurally similar to interleukin 2 (IL-2), IL-15 supports the persistence of CD8 memory T cells while inhibiting IL-2-induced T cell death that better maintains long-term anti-tumor immunity.
View Article and Find Full Text PDFCell-based immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy, has revolutionized the treatment of hematological malignancies, especially in patients who are refractory to other therapies. However, there are critical obstacles that hinder the widespread clinical applications of current autologous therapies, such as high cost, challenging large-scale manufacturing, and inaccessibility to the therapy for lymphopenia patients. Therefore, it is in great demand to generate the universal off-the-shelf cell products with significant scalability.
View Article and Find Full Text PDFIntraperitoneal (i.p.) experimental models in mice can recapitulate the process of i.
View Article and Find Full Text PDF